Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...

DexCom (NasdaqGS:DXCM) announced new AI-enabled features for its Stelo glucose monitoring system. The update adds a comprehensive nutrition database, expanded meal tracking, and personalized ...

Feb 12 (Reuters) - Medical device maker Dexcom beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems. The company ...

DexCom (NasdaqGS:DXCM) is upgrading its Stelo glucose monitoring platform with AI driven features that expand its nutrition database and deliver more personalized health insights. The new tools focus ...

Nearly six months after the Food and Drug Administration (FDA) approved Dexcom’s over-the-counter continuing glucose monitor (CGM), the company has launched the product. The CGM – dubbed Stelo – made ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...

In March, the FDA approved DexCom Inc‘s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...